SCYNEXIS Enters Material Definitive Agreement on Dec 26, 2023

TL;DR

**SCYNEXIS just signed a big deal, watch for details on what it means for the stock.**

AI Summary

SCYNEXIS, Inc. filed an 8-K on January 2, 2024, reporting an "Entry into a Material Definitive Agreement" that occurred on December 26, 2023. This filing indicates a significant new contract or partnership for the pharmaceutical company, which could impact its future revenue streams or operational structure. For investors, this matters because material agreements often signal strategic shifts, potential growth opportunities, or changes in financial outlook, directly influencing the stock's valuation.

Why It Matters

This filing signals a new, important business agreement for SCYNEXIS, Inc., which could lead to new revenue, partnerships, or strategic changes, potentially affecting the company's financial performance and stock price.

Risk Assessment

Risk Level: medium — The filing indicates a material agreement but lacks specific details, creating uncertainty about its financial impact and implications for SCYNEXIS, Inc.

Analyst Insight

Investors should monitor SCYNEXIS, Inc.'s upcoming announcements for specific details regarding the "Material Definitive Agreement" to assess its potential impact on the company's financials and strategic direction before making investment decisions.

Key Players & Entities

• SCYNEXIS, Inc. (company) — the registrant filing the 8-K
• December 26, 2023 (date) — date of the earliest event reported (entry into material definitive agreement)
• January 2, 2024 (date) — date the 8-K was filed
• 001-36365 (other) — Commission File Number for SCYNEXIS, Inc.
• SCYX (other) — trading symbol for SCYNEXIS, Inc. Common Stock
• The Nasdaq Global Market (other) — exchange where SCYNEXIS, Inc. Common Stock is registered

Forward-Looking Statements

• SCYNEXIS, Inc. will release further details about the material definitive agreement in a subsequent filing or press release. (SCYNEXIS, Inc.) — high confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share SCYX The Nasdaq Global Ma
• $90 million — already received an upfront payment of $90 million and a development milestone payment of
• $25 million — and a development milestone payment of $25 million. Under the terms of the updated License
• $49 million — ry approval milestone payments of up to $49 million (revised from up to $70 million as prov
• $70 million — f up to $49 million (revised from up to $70 million as provided in the License Agreement);
• $57.5 million — commercial milestone payments of up to $57.5 million based on first commercial sale in invas
• $115 million — ndidiasis (U.S./EU) (revised from up to $115 million as provided in the License Agreement);
• $179.5 — ; and sales milestone payments of up to $179.5 / $169.75 / $145.5 million (depending o
• $169.75 — es milestone payments of up to $179.5 / $169.75 / $145.5 million (depending on the date
• $145.5 million — ne payments of up to $179.5 / $169.75 / $145.5 million (depending on the date of GSK’s
• $242.5 million — AFEMME in the U.S.) (revised from up to $242.5 million as provided in the License Agreement).
• $64 — s in the GSK Territory, with a total of $64 / $54.25 / $46.5 million to be paid upo
• $54.25 — he GSK Territory, with a total of $64 / $54.25 / $46.5 million to be paid upon achieve
• $46.5 million — rritory, with a total of $64 / $54.25 / $46.5 million to be paid upon achievement of multiple
• $200 million — of multiple sales thresholds up through $200 million; a total of $45.5 / $45.5 / $39 million

Filing Documents

• scyx-20231226.htm (8-K) — 44KB
• 0000950170-24-000238.txt ( ) — 159KB
• scyx-20231226_lab.xml (EX-101.LAB) — 13KB
• scyx-20231226_pre.xml (EX-101.PRE) — 10KB
• scyx-20231226.xsd (EX-101.SCH) — 2KB
• scyx-20231226_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. Binding Memorandum of Understanding for Amendment to License Agreement with GSK On December 26, 2023, SCYNEXIS, Inc. (“SCYNEXIS”) and GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”) entered into a binding memorandum of understanding (“Binding MOU”) for amendment to the exclusive license agreement between SCYNEXIS and GSK, dated March 30, 2023 (the exclusive license agreement, together with the associated Transitional Manufacturing and Supply Agreement, the “License Agreement”). Pursuant to the terms of the License Agreement, SCYNEXIS granted GSK an exclusive (even as to SCYNEXIS and its affiliates), royalty-bearing, sublicensable license for the development, manufacture, and commercialization of ibrexafungerp, including the approved product BREXAFEMME , for all indications, in all countries other than Greater China and certain other countries already licensed to third parties (the “GSK Territory”). The terms of the License Agreement are further described in SCYNEXIS’s Form 8-K dated March 30, 2023. As disclosed on September 25 th , 2023, SCYNEXIS became aware that a non-antibacterial beta-lactam drug substance is manufactured using equipment common to the manufacturing process for ibrexafungerp. Current FDA draft guidance recommends segregating the manufacture of non-antibacterial beta-lactam compounds from other compounds since beta-lactam compounds have the potential to act as sensitizing agents that may trigger hypersensitivity or an allergic reaction in some people. In the absence of the recommended segregation, there is a risk of cross contamination. It is not known whether any ibrexafungerp has been contaminated with a beta-lactam compound. Nonetheless, in light of this risk and out of an abundance of caution, BREXAFEMME (ibrexafungerp tablets) was recalled from the market and clinical studies of ibrexafungerp w

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SCYNEXIS, Inc. Date: January 2, 2024 By: /s/ David Angulo Name: David Angulo, M.D. Its: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR